Abstract. Transient receptor potential cation channel, subfamily C, member 1 (TRPC1) participates in many physiological functions but has also been implicated in cancer development. However, little is known about the role of TRPC1 in ovarian cancer (OC), including the drug resistance of these tumors. In the present study, a significant and consistent downregulation of TRPC1 in drug-resistant OC tissues/cells was determined using real-time quantitative polymerase chain reaction assays and the microarrays deposited in Oncomine and Gene Expression Omnibus (GEO) Profiles. Protein/gene-protein/gene and protein-chemical interactions indicated that TRPC1 interacts with 14 proteins/genes and 6 chemicals, all of which are involved in the regulation of drug resistance in OC. Biological process annotation of TRPC1, OC, and drug resistance indicated a role for TRPC1 in drug-resistance-related functions in OC, mainly via the cell cycle, gene expression and cell growth and cell death. Analysis of mRNA-microRNA interactions showed that 8 out of 11 major pathways enriched from 38 predominant microRNAs targeting TRPC1 were involved in the regulation of drug resistance in OC, and 8 out of these top 10 microRNAs were implicated in the drug resistance in ovarian and other cancers. In a clinical analysis using data obtained from The Cancer Genome Atlas project (TCGA) cohort on 341 OC patients, TRPC1 expression was found to differ significantly between grade 2 and grade 3 tumors, with low-level expression correlating with higher tumor grade. This is the first report to show a potential association between the downregulation of TRPC1 and both drug resistance and high histological tumor grade in OC. Our results provide the basis for further investigations of the drug-resistance-related functions of TRPC1 in OC and other forms of cancer.

Introduction

The treatment of ovarian cancer (OC) has improved over the past 30 years, following the introduction of platinum- and paclitaxel-based chemotherapy. However, most patients with OC will suffer disease relapse despite having achieved a complete clinical response. In many of these patients, the disease is incurable mainly owing to the development of drug resistance (1). Treatment failure and death from OC have been attributed to drug resistance in >90% of patients with metastatic disease. Thus, a better understanding of the mechanisms of drug resistance in OC will lead to improved treatment strategies and perhaps, better survival (2).

Drug resistance in OC is the product of a myriad of contributing factors (3). These include microRNA and long non-coding RNA regulation, increased DNA damage tolerance/repair, increased or altered drug targets, growth factor receptor deregulation, increased anti-apoptotic regulator activity and metabolic disturbances (4-7). Underlying or accompanying these factors is the dysregulation of critical genes (8). Richardson and Kaye (9) described several gene families that may contribute to the evolution of drug resistance in OC, via pathways involving DNA damage, apoptosis and cell-survival signaling. In previous studies, we identified 15 tumor suppressor genes (TSGs) and 25 oncogenes that contribute to drug resistance in OC through DNA damage, apoptosis, cell cycle interactions, DNA binding and the AKT and BAX-mediated signaling pathways (8,10). Thus, the identification of drug-resistance-related genes and investigation of their contribution to drug resistance may offer solutions to the successful treatment of patients with OC.

The cellular entry of extracellular Ca2+ and the subsequent elevation of the intracellular Ca2+ concentration are key events in cell cycle progression (11). Indeed, Ca2+-mediated signaling is associated with many features of cancer, including the development of drug resistance (12,13). Cellular Ca2+ entry is mediated by transient receptor poten-
tial (TRP) proteins. These are non-selective cation channels that are permeable to Ca$^{2+}$ (14) and fulfill diverse roles as versatile cellular sensors and effectors (15). TRPC1 was the first cloned mammalian TRP protein. It is found in a wide variety of tissues, where it contributes to physiological functions such as cell proliferation, differentiation, cell migration, membrane permeability, fluid secretion, smooth and skeletal muscle function, wound healing and protection against cell death (16). Moreover, TRPC1 is also involved in the regulation of cancer development and was shown to play an important role in apoptosis in hepatocellular carcinoma (17), the metastasis of nasopharyngeal carcinoma (18), and in promoting cell proliferation in non-small cell lung carcinoma cell lines (19). In OC, TRPC1 was shown to be essential in promoting cell proliferation and tumorigenesis (20). However, the exact role of TRPC1 in cancer is poorly understood and whether it contributes to drug resistance in OC has never been determined.

In the present study, we provide evidence of a marked decrease in TRPC1 mRNA levels in human OC vs. normal specimens/cells and of their downregulation in drug-resistant OC vs. sensitive cells. Comprehensive bioinformatics analyses suggested the interaction of TRPC1 with numerous proteins, genes, chemicals, biological processes and microRNAs, all of which are involved in the regulation of OC drug resistance. In addition, lower TRPC1 expression was shown to correlate with genes, chemicals, biological processes and microRNAs, all of which are involved in the regulation of OC drug resistance. For GAPDH, used as the control, the forward primer was 5'-GAAGATGGTGATGGGATTT-3' and (reverse primer) 5'-CCCGACATCTGTCCAAACCA-3'. Gene expression profiles. TRPC1 mRNA expression data were retrieved from Oncomine (https://www.oncomine.org/resource/login.html) (21) and GEO Profiles (http://www.ncbi.nlm.nih.gov/geoprofiles/) (22). Welsh Ovarian Statistics, Bonome Ovarian Statistics and Yoshihara Ovarian Statistics data are deposited in Oncomine. The level of TRPC1 mRNA expression between OC and normal controls in the Oncomine microarrays are presented as fold changes; significant differences are indicated based on their P-value. Microarrays GDS3592, GDS3754 and GDS1381 are deposited in GEO Profiles. In this database, in the case of two probe sets targeting one gene, only the probe set with significant statistical variability was retained. In the case of more than three probe sets targeting one gene, the set exhibiting the most divergent expression was excluded and the set with significant statistical variability was retained. The expression data of TRPC1 and microRNAs, and clinical data of 489 OC patients registered in The Cancer Genome Atlas (TCGA) cohort was retrieved from the cBioPortal for Cancer Genomics (http://cbioportal.org) (23,24).

Bioinformatics analyses. Protein/gene interactions were determined using the GeneMANIA online tool (http://www.genemania.org/) (25). Protein/small-molecule/chemical interactions were analyzed using STITCH (http://stitch.embl.de/) (26,27). Biological processes were annotated using the Coremine Medical tool (http://www.coremine.com/medical/) (28). Interactions between microRNA and mRNA were predicted using miRWalk (http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/) (29), for which eight prediction programs (DIANAmT, miRanda, miRDB, miRWalk, RNAhybrid, PICTAR5, RNA22 and TargetScan) were selected; the same microRNA predicted by at least six of them was selected for further analysis. Pathway enrichment analysis of microRNAs was performed using the DIANA-mirPath web server (http://diana.cslab.ece.ntua.gr/pathways/) (30).

Data analysis. The data were analyzed using the SPSS 20.0 software. The mRNA expression level of a particular gene is shown as the mean ± SD. The homogeneity of the variance was analyzed using the t-test. The probability of survival and significance were calculated using the Kaplan-Meier method and a log-rank test. The correlation between microRNAs and the gene was analyzed using bivariate correlations. The correlation between gene expression and the clinicopathological characteristics was evaluated by Pearson's $\chi^2$ test (2-sided). Expression values of a gene were dichotomized into high and low expression using the median as a cut-off in a Kaplan-Meier analysis, in accordance with previous studies (31,32). A P-value <0.05 was considered to indicate statistical significance.

Results

TRPC1 is significantly downregulated in OC and drug-resistant OC tumor specimens/cells. TRPC1 mRNA expression was significantly and consistently downregulated in OC tissues and cells compared with the expressions in normal controls, as determined using data retrieved from microarrays deposited in Oncomine and GEO Profiles. As indicated in Fig. 1A, TRPC1 mRNA expression was downregulated by 3.955-, 3.681- and
3.260-fold in OC specimens according to the Oncomine Welsh ovarian microarray, covering 28 ovarian serous surface papillary carcinomas and four normal ovarian tissues; the Bonome ovarian microarray, TRPC1 expression is downregulated 3.681-fold ($P=6.84\times10^{-9}$) in the 185 ovarian carcinomas compared with the 10 normal ovarian surface epithelium samples. Y, Yoshihara ovarian microarray. TRPC1 expression is downregulated 3.260-fold ($P=2.08\times10^{-9}$) in the 38 ovarian serous adenocarcinomas compared with the 10 peritoneal tissues. (B) TRPC1 mRNA expression in normal ovarian surface epithelia and in OC epithelial cells as determined using microarray data (GDS3592) retrieved from GEO Profiles. Normal ovarian surface epithelial cells were collected from ovaries at the time of surgery using a Cytobrush Plus; tumor tissues were surgically removed and collected for cell isolation. The normalized data were deposited in GEO Profiles (33). Twelve biological replicates were obtained for the normal cells and tumor cells. I, GDS3592/205803_s_at/TRPC1; II, GDS3592/205802_at/TRPC1. **$P<0.001$.

Comprehensive analyses indicating potential associations of TRPC1 with drug resistance in OC

Functional prediction and analysis based on protein/gene-protein/gene interactions. The protein/gene interactions of TRPC1 with other proteins/genes were analyzed using the GeneMANIA tool. The query in red includes the proteins/genes that interact directly with TRPC1, and the query in blue includes the drug resistant-related proteins/genes that interact indirectly with TRPC1. The types of interactions between proteins/genes are indicated in the network legend of the figure.
programmed cell death 4 (PDCD4), MET proto-oncogene, receptor tyrosine kinase (MET), oxoglutarate dehydrogenase-like (OGDHL), B-cell CLL/lymphoma 2 (BCL2), phosphatase and tensin homolog (PTEN), SPARC-like 1 (hevin) (SPARCL1) and phosphatidylinositol 3-kinase, catalytic subunit type 3 (PIK3C3). Except for MORC4, all of these genes/proteins have been implicated in the regulation of drug resistance in OC. For example, PTEN is a TSG involved in the regulation of drug resistance via the PI3K/AKT pathway and the p53-mediated apoptotic cascade. A reduction in PTEN expression confers resistance to cisplatin in OvCAR-3 cells through the activation of PI3K/Akt (36), and the overexpression of PTEN reverses chemoresistance to cisplatin in human OC cells by inactivating the PI3K/AKT cell survival pathway (37). However, in another study, the overexpression of PTEN upregulated p53 and increased the sensitivity of chemoresistant cells to cisplatin-induced apoptosis without detectable changes in the levels of phospho-Akt, suggesting that PTEN regulates drug resistance through a p53-mediated apoptotic cascade independent of the PI3K/Akt pathway (38). In a recent study, the overexpression of PTEN improved the cisplatin-resistance of human OC cells by upregulating the PI3K/Akt pathway (39). In another study, the overexpression of PTEN upregulated p53 and increased the sensitivity of chemoresistant cells to cisplatin-induced apoptosis without detectable changes in the levels of phospho-Akt, suggesting that PTEN regulates drug resistance through a p53-mediated apoptotic cascade independent of the PI3K/Akt pathway (38). In a recent study, the overexpression of PTEN improved the cisplatin-resistance of human OC cells by upregulating the PI3K/Akt pathway (39). In another study, the overexpression of PTEN upregulated p53 and increased the sensitivity of chemoresistant cells to cisplatin-induced apoptosis without detectable changes in the levels of phospho-Akt, suggesting that PTEN regulates drug resistance through a p53-mediated apoptotic cascade independent of the PI3K/Akt pathway (38). In a recent study, the overexpression of PTEN improved the cisplatin-resistance of human OC cells by upregulating the PI3K/Akt pathway (39). In another study, the overexpression of PTEN upregulated p53 and increased the sensitivity of chemoresistant cells to cisplatin-induced apoptosis without detectable changes in the levels of phospho-Akt, suggesting that PTEN regulates drug resistance through a p53-mediated apoptotic cascade independent of the PI3K/Akt pathway (38). In a recent study, the overexpression of PTEN improved the cisplatin-resistance of human OC cells by upregulating the PI3K/Akt pathway (39). In another study, the overexpression of PTEN upregulated p53 and increased the sensitivity of chemoresistant cells to cisplatin-induced apoptosis without detectable changes in the levels of phospho-Akt, suggesting that PTEN regulates drug resistance through a p53-mediated apoptotic cascade independent of the PI3K/Akt pathway (38).
Prediction and analysis of function based on the annotation of biological processes. The Gene Ontology (GO) consortium (59) provides a valuable source of structured knowledge of protein function in terms of molecular function, biological processes and cellular components. A gene may be involved in one or more biological processes (60), and the involvement of a gene in a given biological process can be used to predict the biological role and function of that gene (61). The Coremine Medical online database can be publicly accessed by anyone seeking information on health, medicine and biology (28,62). It can be used to analyze the associations between genes, biological processes and drug resistance. As shown in Fig. 5, 17 biological processes significantly associated with TRPC1, OC and drug resistance were annotated (P<0.01). Given the close relationships of TRPC1 with these processes, and their close relationships with OC and drug resistance, TRPC1 is likely to be involved in the regulation of drug resistance in OC. Six of those processes are cell-growth- and cell death-related, three are cell cycle-related and 3 are gene expression-related (Fig. 5). Thus, the drug-resistance-related functions of TRPC1 in OC are likely to reflect its involvement in the cell cycle, gene expression, and in particular, cell growth and cell death.

Functional prediction based on the functionality of microRNAs that target the TRPC1 gene. MicroRNA-mediated post-transcriptional gene regulation is an important regulator of many cellular processes, both physiological and pathological (63,64). The target genes of microRNAs are a focus of interest based on their diagnostic, prognostic and therapeutic relevance (65), and the function of a gene can be predicted based on functionality of the microRNAs that target it (41). To identify microRNAs that target TRPC1, a microRNA-mRNA interaction analysis was performed with miRWalk, which resulted in the identification of 481 microRNAs predicted to transcriptionally target TRPC1 and suggested the regulation of TRPC1 by microRNA. Those microRNAs predicted by at least 6 of the 8 prediction tools were submitted to pathway enrichment using DIANA miRPath (30).

Table I. Top 11 enriched pathways modulated by microRNAs targeting TRPC1 and their associations with drug resistance in ovarian cancer.

<table>
<thead>
<tr>
<th>MicroRNAs</th>
<th>KEGG pathway</th>
<th>P-value</th>
<th>Regulation of drug resistance in ovarian cancer (Refs.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>hsa-miR-135b, 135a, 603, 186, 497, 548b-3p, 188-5p, 612, 26a, 103, 10b, 570, 590-3p, 195, 548c-5p, 324-3p, 410, 107, 573, 142-5p, 548c-3p, 15a, 338-5p, 16, 577, 548a-5p, 543, 548d-3p, 424, 559, 605, 340, 943, 495, 15b, 607, 101, 641</td>
<td>Pathways in cancer</td>
<td>4.12E-29</td>
<td>Cancer pathway</td>
</tr>
<tr>
<td></td>
<td>PI3K-Akt signaling pathway</td>
<td>3.57E-27</td>
<td>Yes (36,70)</td>
</tr>
<tr>
<td></td>
<td>MAPK signaling pathway</td>
<td>1.20E-21</td>
<td>Yes (71,72)</td>
</tr>
<tr>
<td></td>
<td>HTLV-1 infection</td>
<td>1.83E-20</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Regulation of actin cytoskeleton</td>
<td>2.20E-18</td>
<td>Yes (73)</td>
</tr>
<tr>
<td></td>
<td>Endocytosis</td>
<td>3.88E-18</td>
<td>Yes (74)</td>
</tr>
<tr>
<td></td>
<td>Focal adhesion</td>
<td>1.29E-17</td>
<td>Yes (75)</td>
</tr>
<tr>
<td></td>
<td>Transcriptional misregulation in cancer</td>
<td>2.08E-17</td>
<td>Cancer pathway</td>
</tr>
<tr>
<td></td>
<td>Wnt signaling pathway</td>
<td>3.72E-15</td>
<td>Yes (76)</td>
</tr>
<tr>
<td></td>
<td>Protein processing in endoplasmic reticulum</td>
<td>3.72E-15</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Hepatitis B</td>
<td>3.95E-15</td>
<td>-</td>
</tr>
</tbody>
</table>

The microRNAs predicted by at least six of the eight prediction tools (DIANAmT, miRanda, miRDB, miRWalk, RNAhybrid, PICTAR5, RNA22 and TargetScan) were submitted to pathway enrichment using DIANA miRPath (30).

Table I. Top 11 enriched pathways modulated by microRNAs targeting TRPC1 and their associations with drug resistance in ovarian cancer.

reversed by verapamil (58). Since TRPC1 is an activator of calcium, these results also suggest its involvement in drug resistance.
Taxol resistance and is therefore of interest in the development of microRNA therapies for OC (69).

Taken together, these results provide further support for the involvement of TRPC1 in drug resistance in OC.

Low-level expression of TRPC1 correlates with higher histological tumor grade in a TCGA cohort. We next examined the expression profile and clinical significance of TRPC1 in a TCGA cohort. The clinical data of 489 patients with OC for whom TRPC1 mRNA expression data were available was retrieved from cbioPortal for Cancer Genomics (http://cbioportal.org) (23,24). Data from the 341 patients with complete characteristics, including disease-free survival and status, overall survival and status, histological grade of the neoplasm, primary therapy outcome and tumor stage, were evaluated for an association of drug resistance in OC and TRPC1 expression. Gene expression was categorized high or low by the median value in accordance with a previous study (31). As shown in Table III, TRPC1 expression differed significantly between patients with grade 2 (moderately-differentiated) OC and those with grade 3 (poorly-differentiated) OC (P=0.006). Low-level expression correlated with higher tumor grade. A comparison of the disease-free and overall survival of the 341 OC patients with TRPC1 expression above or below the median level showed a disadvantage in terms of overall survival for patients with low vs. high expression (48.700±2.307 vs. 51.300±2.843), although the difference was not statistically significant.

Discussion

Tumorigenesis and tumor progression are driven by the aberrant function of genes that regulate genome stability, cell proliferation, apoptosis, angiogenesis, cell cycle, invasion, metastasis and drug resistance (89). With the rapid development of high-throughput technologies, databases such as GEO Profiles (22) and TCGA (90) have provided high-resolution molecular profiles of gene expression, microRNA expression, copy number and methylation in cancer tissues. In the present study, microarray data retrieved from GEO and TCGA were used to analyze TRPC1 expression in OC and its clinical relevance.

Bioinformatics analysis based on the various proteomic and genomic datasets can exploit the context of a protein/gene in cellular networks, provide insights into the functional role of a protein/gene, facilitate the rapid annotation of protein/gene function, and thereby guide laboratory experiments (91-94). For example, a comprehensive bioinformatics approach, including microarrays, motif analysis, protein/gene interaction, protein-chemical interaction, biological process annotation, pathway enrichment and mRNA-microRNA interactions, has been used to identify the association of dysregulated SPARCL1 and chemokine (C-C motif) ligand 21 (CCL21) (41), NIMA-related kinase 11 (NEK11) (95) and NIMA-related kinase 2 (NEK2) (96), and ribonuclease T2 (RNASET2) and gametogenetin binding protein 2 (GGNBP2) (97) with drug resistance in
In hepatocellular and gastric carcinomas, bioinformatics analysis revealed the association of E2F transcription factor 3 (E2F3) (98) and spalt-like transcription factor 4 (SALL4) (99), respectively, with prognosis. In this study, widely used bioinformatics tools and networks, including GeneMania (25), STITCH (version 4.0) (26,27), Coremine Medical (28), and DIANA miRPath (30), and six mRNA-microRNA prediction tools, including TargetScan, were used to analyze the associations of TRPC1 with drug resistance in OC.

TRPC1 mRNA expression was significantly and consistently downregulated by at least 3.260-fold in 251 OC samples compared with 24 normal control samples, according to three independent microarrays (Fig. 1A). In a previous study TRPC1 mRNA expression was lower in 5 ovarian serous papillary adenocarcinomas than in five normal samples (20). TRPC1 mRNA was at least 3-fold lower in OC cells than in normal ovarian surface epithelial cells (Fig. 1B). Significant downregulation of TRPC1 mRNA was also detected in cisplatin-resistant A2780 and SKOV3 cells and carboplatin-resistant A2780 cells when compared with expression in their sensitive counterparts (Fig. 2). These results indicated that the stable and significant downregulation of TRPC1 in OC and drug-resistant cells plays a critical role in the development of OC and in the regulation of drug resistance.

Further support for this conclusion was obtained in a comprehensive bioinformatics analyses. Protein/gene-protein/gene and protein-chemical interactions indicated the interaction of TRPC1 with 14 proteins/genes and 6 chemicals, all of which are associated with drug resistance in OC (Figs. 3 and 4). Annotation of TRPC1, OC and drug resistance supported a role for TRPC1 in drug-resistance-related functions in OC through 17 biological processes related to the cell cycle, gene expression and cell growth and cell death (Fig. 5). Among the top 11 pathways enriched from the top 38 microRNAs targeting TRPC1, 8 were involved in the regulation of drug resistance in OC (Table I). In addition, 8 of the top 10 microRNAs targeting TRPC1 were implicated in drug resistance in ovarian and other cancers (Table II).

A possible mechanism underlying the role of TRPC1 in drug resistance in OC is the regulation of autophagy. As shown in Fig. 3, co-expression and genetic interactions between TRPC1 and PIK3C3 and co-expression and co-localization with SPARCL1 were determined. PIK3C3 plays a critical role in the regulation of autophagy in vitro and in vivo (100). Autophagy, which acts both in protecting against cancer as well as promoting the growth of cancer, has attracted increased attention as an important mechanism for cancer development (101). Autophagy also contributes to drug resistance in ovarian and other cancers (101,102). For instance, it has been reported that the induction of ERK-mediated autophagy conferred cisplatin resistance to ovarian cancer cells (103). The relationship between PIK3C3 and cancer has been targeted in chemotherapy via the drug paclitaxel, which has been used to block PIK3C3 activation (104). SPARCL1 was shown to be involved in the regulation of drug resistance via several pathways, including autophagy (41). The strong interactions of SPARCL1 with TRPC1 suggest the involvement of the latter in the regulation of autophagy and in drug resistance in OC.

Finally, our analysis of the relationship between TRPC1 mRNA expression and the histological grade of OC in 341 patients of a TCGA cohort showed significant differences between grade 2 (moderately-differentiated) and grade 3 (poorly-differentiated) tumors, with the low-level expression of TRPC1 correlating with high tumor grade (Table III). This result provides clinical support for a link between the down-regulation of TRPC1 and drug resistance in OC.

In summary, evidence obtained from RT-qPCR measurement, microarray data retrieval, comprehensive bioinformatics analyses, and clinical analysis of a TCGA cohort together suggest that the downregulation of TRPC1 contributes to drug resistance in OC and to the high histological grade of these OC.

<table>
<thead>
<tr>
<th>Table III. Correlation between TRPC1 expression and the clinicopathological characteristics of 341 patients with ovarian cancer.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Characteristics</td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td>Histological grade</td>
</tr>
<tr>
<td>Grade 2</td>
</tr>
<tr>
<td>Grade 3</td>
</tr>
<tr>
<td>Primary therapy outcome</td>
</tr>
<tr>
<td>Complete response</td>
</tr>
<tr>
<td>Partial response</td>
</tr>
<tr>
<td>Progressive disease</td>
</tr>
<tr>
<td>Stable disease</td>
</tr>
<tr>
<td>Tumor stage</td>
</tr>
<tr>
<td>II</td>
</tr>
<tr>
<td>III</td>
</tr>
<tr>
<td>IV</td>
</tr>
</tbody>
</table>

*Evaluated using Pearson's χ² test (2-sided).
tumors. Our results provide the basis for further investigation of the drug-resistance-related functions of TRPC1 in OC.

Acknowledgements

The present study was supported by the National Science Foundation of China (grant nos. 81302283, 81506042 and 81460397), the Chinese Postdoctoral Science Foundation (nos. 2014M552355XB and 2014M552291), the National Science Foundation of Guangxi (nos. 2014GXNSFCA118010, 2015GXNSFBA139115, 2015GXNSFAA139151 and 2014GXNSFBA118155), and the Youth Foundation of Guangxi Medical University (no. GXMYSF201312).

References


Hiss DC, Gabriels GA and Folb PI: Combination of tunicamycin with anticancer drugs synergistically enhances their toxicity in multidrug-resistant human ovarian cystadenocarcinoma cells. Cancer Chemother Pharmacol 5: 227-232, 1980.


